Across TCGA pan-cancer cohorts, TTC29 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TTC29 data layer compared with 17 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher TTC29 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC29 expression acts as an unfavorable survival marker.
GBM are the cancer types where TTC29 mass-spec protein most reproducibly stratifies survival.